Julius Clinical’s Post

Cell & gene therapies need special considerations when it comes to designing your clinical trial. Set up a meeting with our colleagues in London to learn more about our experience. #geneediting #advancedtherapies #genetherapies

Homozygous familial hypercholesterolemia is an inherited metabolic disorder that increases #cardiovascular disease risk and has limited treatment options. Read about our exciting preclinical results presented at the American Society of Gene & Cell Therapy Annual Meeting 2024 using our #genetherapy asset NGGT-006 to restore low density lipoprotein receptor function: https://lnkd.in/eKiSKA4

📚 In this Friday read, we spotlight a study published in Nature Communications aimed at increasing the efficacy of CAR T therapy by combining it with STING agonists. Researchers used the nCounter platform to analyze gene expression, revealing increased T cell activation and infiltration into tumors 👉https://lnkd.in/dM9a_SBM This combination improved survival and tumor control in models, presenting a promising strategy for enhancing CAR T therapy efficacy. #CARTherapy #CancerResearch #FridayRead

Cell & gene therapies need special considerations when it comes to designing your clinical trial . Our team are attending this great conference and would welcome a discussion with you to share our experiences. #cellandgenetherapy #advancedtherapies

📖 Dive into this #Fridayread and learn how CosMx was used to unveil gene sets linked to treatment response in ulcerative colitis 👉https://bit.ly/3THFViP Scientists from University of California, San Francisco explore how anti-integrin therapy impacts lymphocyte trafficking in ulcerative colitis. Through the lens of single-cell spatial-omics, they delve into cellular networks involving mononuclear phagocytes and fibroblasts describing a spatial atlas for colitis. #singlecellspatial #inflammation #ulcerativecolitis

Discover how AI is revolutionizing cancer therapy with advancements like Profluent's OpenCRISPR-1. Explore its potential in enhancing gene editing and patient outcomes. https://lnkd.in/gKyksunT

While 2023 was the year of gene therapy, 2024 is already shaping up to be the year of cell therapy. Today, we have released our April 2024 Sector Snapshot, which focuses on recent key advancements propelling engineered cell therapies. In this edition, you will find:   📋 An updated 2024 clinical pipeline outlook 🔬 Review of the cell therapy clinical landscape 🧫 Trends driving cell therapy development Read it here: https://lnkd.in/exkeE8bJ #Celltherapy #Oncology

Scientists have created a comprehensive map of all possible changes within a key tumor suppressor gene, VHL. This detailed picture, a first step in a larger project, could help doctors assess cancer risk and tailor treatment for patients with VHL gene variations. #TalentInfluencersLeaderboard #FortreaAlwaysOn #Fortrea https://lnkd.in/dHn-zJXu

Interesting Review in the field of DNA/RNA Therapeutics! Our product, in vivo-jetPEI®, has been featured prominently in the recent peer-reviewed paper titled "Polyethylenimine (PEI) in gene therapy: Current status and clinical applications," authored by J. Casper et al. 📑 This comprehensive review delves into the Research & Development and Clinical applications of PEI, illustrating the use of in vivo-jetPEI®, as a reference delivery tool for developing localized DNA-based treatments for solid tumors and therapeutic vaccination. The paper also showcases the clinical use of in vivo-jetPEI® as a successful and proven excipient for the delivery of DNA/RNA therapeutics through a detailed table summarizing numerous clinical trials over the years. To read the article : https://lnkd.in/ejc2XhGs. #Polyplus #Sartorius #invivo

I was in Barcelona last week for the 7th Annual Cell & Gene Therapy Innovation Summit, where I had the opportunity to talk about the importance of bringing the potential of cell therapy to more people living with cancer. This topic is especially critical today, as we know that only a fraction of eligible patients receive #celltherapy. To overcome these barriers, everyone in the cell therapy space must work together – and always keep our focus on supporting patients and their physicians – as we aim to change the current landscape. This includes scaling manufacturing capacity to meet patient demand; developing a global network of treatment centers to bring therapies closer to patients; working on ways we can increase patient access; and coordinating the connections between oncologists and treatment centers to support each patient’s journey. #cgti